Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.

BACKGROUND Abnormalities involving the p16 (also known as cyclin-dependent kinase N2 [CDKN2], p16 [INK4a], or MTS1) and p53 (also known as TP53) tumor suppressor genes are highly prevalent in esophageal adenocarcinomas. Loss of heterozygosity (LOH) at 9p21 and 17p13 chromosomes (locations for p16 and p53 genes, respectively) is frequently observed in the premalignant condition, Barrett's esophagus. We studied extensively the distribution and heterogeneity of LOH at 9p and 17p chromosomes throughout the Barrett's segment in patients who have not yet developed esophageal adenocarcinoma. METHODS We evaluated 404 samples from 61 consecutive patients enrolled in the Seattle Barrett's Esophagus Study from February 1995 through September 1998. All patients had high-grade dysplasia but no diagnosis of cancer. The samples were assayed for LOH at 9p and 17p chromosomes after amplification of genomic DNA by use of polymerase chain reaction and DNA genotyping. The cell fractions were purified by flow cytometry on the basis of DNA content and proliferation-associated antigen labeling. Association between LOH at 9p and LOH at 17p with flow cytometric abnormalities was determined by chi-squared test, and logistic regression models were used to model and test for the extent to which a particular genotype was found in 2-cm intervals. RESULTS AND CONCLUSIONS LOH at 9p and 17p chromosomes are highly prevalent somatic genetic lesions in premalignant Barrett's tissue. LOH at 9p is more common than LOH at 17p in diploid samples and can be detected over greater regions of Barrett's epithelium. In most patients with high-grade dysplasia, the Barrett's mucosa contains a mosaic of clones and subclones with different patterns of LOH. Some clones had expanded to involve extensive regions of Barrett's epithelium. LOH at 9p and 17p chromosomes may be useful biomarkers to stratify patients' risk of progression to esophageal cancer.

[1]  M. Emond,et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.

[2]  P. Maxwell,et al.  Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. , 1998, British Journal of Cancer.

[3]  M. Beckmann,et al.  Frequent allele loss on 9p21–22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer , 1996, Genes, chromosomes & cancer.

[4]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[5]  B. Reid,et al.  Barrett's esophagus: a model of human neoplastic progression. , 1994, Cold Spring Harbor symposia on quantitative biology.

[6]  B. Reid,et al.  p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.

[7]  C. McConkey,et al.  The rising trend in oesophageal adenocarcinoma and gastric cardia. , 1992, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[8]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[9]  G. Eastwood,et al.  Cell proliferation in three types of Barrett's epithelium 1 , 1980, Gut.

[10]  G. Thomas,et al.  Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.

[11]  Patricia L. Blount,et al.  Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Reid,et al.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. , 1987, Gastroenterology.

[13]  D. Levine.  Management of dysplasia in the columnar-lined esophagus. , 1997, Gastroenterology clinics of North America.

[14]  J B Wong,et al.  A guide for surveillance of patients with Barrett's esophagus. , 1994, The American journal of gastroenterology.

[15]  S. Hirohashi,et al.  Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. , 1992, Cancer research.

[16]  G. Chejfec,et al.  High grade dysplasia still is not an indication for surgery in patients with Barrett's esophagus: An update , 1998 .

[17]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[18]  B. Reid,et al.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. , 1988, Gastroenterology.

[19]  W. Hop,et al.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.

[20]  O. Yoshida,et al.  Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. , 1998, Cancer research.

[21]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[22]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[23]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[24]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[25]  Carissa A. Sanchez,et al.  17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. , 1991, Cancer research.

[26]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[27]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[28]  J. Minna,et al.  Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.

[29]  R. Sampliner,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997, The American journal of gastroenterology.

[30]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[31]  D. Lane,et al.  Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. , 1992, Gastroenterology.

[32]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[33]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[34]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[35]  M. Berenson,et al.  Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). , 1978, Gastroenterology.

[36]  P. Goodfellow,et al.  Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. , 1996, Cancer research.

[37]  D. Wong,et al.  p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.

[38]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[39]  G. Peters,et al.  Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.

[40]  Carissa A. Sanchez,et al.  Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. , 1993, Gastroenterology.

[41]  J. Abraham,et al.  The MTS1 gene is frequently mutated in primary human esophageal tumors. , 1994, Oncogene.

[42]  B. Vogelstein,et al.  Clonal origin of bladder cancer. , 1992, The New England journal of medicine.

[43]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[44]  C. Purdie,et al.  Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. , 1993, Oncogene.

[45]  J. Peters,et al.  Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. , 1994, The Journal of thoracic and cardiovascular surgery.

[46]  S. Re,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .

[47]  C. Hsieh,et al.  Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. , 1998, Gastroenterology.

[48]  J. V. van Sandick,et al.  Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus , 2000, The Journal of pathology.

[49]  B. Reid,et al.  Barrett's esophagus and esophageal adenocarcinoma. , 1991, Gastroenterology clinics of North America.

[50]  P. Radice,et al.  Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. , 1995, Cancer research.

[51]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[52]  Wong Rk,et al.  Barrett's esophagus. Natural history, incidence, etiology, and complications. , 1991 .

[53]  Carissa A. Sanchez,et al.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[54]  B. Reid,et al.  Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. , 1999, Genome research.

[55]  Jing Yin,et al.  Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. , 1994, Cancer research.

[56]  Flow-cytometric DNA content analysis of esophageal squamous cell carcinomas. , 1991, Gastroenterology.

[57]  R. Sampliner,et al.  Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. , 1989, Gastroenterology.

[58]  B. Reid,et al.  Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[59]  N. Shaheen,et al.  Surveillance for Barrett's esophagus: are we saving lives? , 1997, Gastroenterology.

[60]  Carissa A. Sanchez,et al.  Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. , 1996, Oncogene.

[61]  T. Wright.  High‐grade dysplasia in Barrett's oesophagus , 1997, The British journal of surgery.

[62]  Patricia L. Blount,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .

[63]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[64]  E Gabrielson,et al.  Genetic divergence in the clonal evolution of breast cancer. , 1996, Cancer research.

[65]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[66]  R Montironi,et al.  Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. , 1996, Human pathology.

[67]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[68]  R. Sutton,et al.  Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. , 1998, British Journal of Cancer.

[69]  Carissa A. Sanchez,et al.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. , 1994, Cancer research.

[70]  W. Hong,et al.  Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. , 1993, Cancer research.

[71]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.